<div id="readability-page-1"><p>Korro Bio (NASDAQ:KRRO - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($1.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.61) by $0.69, Zacks reports.</p><h2>Korro Bio Trading Down 4.2%</h2><ul><li>3 Stocks That Could Rise on European Bank Interest Rate Cuts</li></ul><p>Shares of Korro Bio stock traded down $1.38 during midday trading on Wednesday, hitting $31.42. The company had a trading volume of 1,634,378 shares, compared to its average volume of 190,818. The business's 50 day simple moving average is $38.69 and its two-hundred day simple moving average is $23.58. Korro Bio has a 1-year low of $10.29 and a 1-year high of $70.49. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several research analysts recently weighed in on KRRO shares. Raymond James Financial dropped their price target on Korro Bio from $153.00 to $147.00 and set a &#34;strong-buy&#34; rating on the stock in a research report on Wednesday, August 13th. HC Wainwright dropped their target price on Korro Bio from $100.00 to $90.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, August 13th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Korro Bio in a research report on Tuesday, October 14th. Finally, Chardan Capital  reiterated a &#34;buy&#34; rating and issued a $25.00 price objective on shares of Korro Bio in a research note on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned  a Buy rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat.com, Korro Bio  has a consensus rating of &#34;Buy&#34; and a consensus price target of $86.83.</p><p><b>View Our Latest Research Report on KRRO</b></p><h2>Hedge Funds Weigh In On Korro Bio</h2><p>Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of  Korro Bio by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 395,659 shares of the company's stock worth $18,948,000 after purchasing an additional 8,921 shares during the last quarter.  Geode Capital Management LLC boosted its position in  Korro Bio by 10.8% in the second quarter. Geode Capital Management LLC now owns 155,387 shares of the company's stock valued at $1,941,000 after buying an additional 15,166 shares in the last quarter.  Raymond James Financial Inc. grew its stake in  Korro Bio by 357.6% during the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company's stock worth $1,042,000 after buying an additional 65,170 shares during the last quarter.  Finally, Bank of America Corp DE increased its holdings in shares of  Korro Bio by 520.0% during the second quarter. Bank of America Corp DE now owns 28,156 shares of the company's stock worth $352,000 after buying an additional 23,615 shares in the last quarter. 13.18% of the stock is owned by institutional investors and hedge funds. </p><h2>Korro Bio Company Profile</h2> (Get Free Report)<p>Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Korro Bio</li><li>What does consumer price index measure? </li><li>Rare Earth Stocks: The Truce That Isn't a Truce</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>Carving Up Profits: 3 Food Stocks on the Thanksgiving Table</li><li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li><li>C3.ai's Reset: Why New Leadership Could Spark a Turnaround</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JSTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Korro Bio Right Now?</h2><p>Before you consider Korro Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.</p><p>While Korro Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KRRO

<p>Korro Bio (NASDAQ:KRRO) reported quarterly earnings of ($1.92) per share, beating the consensus estimate of ($2.61) by $0.69. Despite the positive earnings surprise, shares fell 4.2% to $31.42. Analysts have mixed ratings, with a consensus "Buy" rating and a price target of $86.83. Hedge funds have adjusted their holdings, with notable increases from Vanguard and Geode Capital. Korro Bio focuses on genetic medicines, with its lead product KRRO-110 in preclinical trials for Alpha-1 Antitrypsin Deficiency.</p>

Korro Bio (NASDAQ:KRRO) Releases Earnings Results, Beats Estimates By $0.69 EPS